SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Visa, Inc. engages in the provision of digital payment services. It also facilitates global commerce through the transfer of value and information among a global network of consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It offers debit cards, credit cards, prepaid products, commercial payment solutions, and global automated teller machines. The company was founded by Dee Hock in 1958 and is headquartered in San Francisco, CA.

Visa Inc - Ordinary Shares - Class A

Visa Inc

Visa is actively trending due to proposals around credit card interest rate caps and a significant settlement with merchants over swipe fees. The community is debating whether a rate cap would directly impact Visa's transaction-based revenue model or primarily affect card-issuing banks, while also noting its strategic moves into stablecoin payments.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending amidst a sharp debate fueled by a recent analyst downgrade and increased competition in the weight management sector, particularly from Amazon Pharmacy's offering of Novo Nordisk's oral GLP-1 pill. The community is divided, with many expressing concern about the stock's valuation and downside potential, while long-term investors see current price levels as a significant buying opportunity, highlighting the company's expanding healthcare verticals and AI integration.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending amid polarized reactions to recent events, with intense community debate surrounding an ICE shooting incident, where some defend law enforcement actions while others decry it as unjustified. Additionally, his public statements about securing oil investments in Venezuela and a potential Greenland acquisition are driving conversations, eliciting both support for his assertive strategies and skepticism regarding their economic and geopolitical implications.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU CRYPTO is consistently trending due to its highly active and dedicated community, which is vigorously building a brand ecosystem with real-world products like Kendu Spice and Energy drinks. The community expresses strong conviction, emphasizing continuous development and IRL presence across multiple chains, positioning KENDU as a long-term play with aspirations for significant market cap growth.

The Aircoin memecoin was born from a viral Twitter post from March, 2014 which proclaimed the following:   Evolution: 1. Aircoin 2. Fartcoin 3. Artcoin  Aircoin was launched in August, 2025 and CTO'd twice, with the second CTO team bringing vast experience and expertise to the project. The team includes industry veterans and visual arts professionals.  Aircoin is destined for greatness as a premier memecoin on the BONK.fun platform.

aircoin

AIRCOIN is trending as its community enthusiastically engages with the AirLock initiative, resulting in over 34% of the token supply being locked. This collective control and "Make Holding Great Again" sentiment, coupled with a prominent celebrity's public endorsement and token lock, is driving immense bullish conversation. The community sees AIRCOIN as a revolutionary meme coin on Solana, emphasizing its unique model for transparency and long-term commitment.

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is trending amid fervent community speculation about an impending "infinity short squeeze" following news of the company eliminating convertible debt. However, sharp price volatility and concerns about potential dilution from registered shares fuel an intense debate, with bulls anticipating significant gains fueled by its low float and innovative material tracking technology, while bears predict further declines.

NovaBay Pharmaceuticals, Inc. engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. Its products include Avenova, NeutroPhase and DERMAdoctor. The company was founded on January 19, 2000 and is headquartered in Emeryville, CA.

Novabay Pharmaceuticals Inc

Novabay Pharmaceuticals Inc. ($NBY) is trending with extreme volatility, primarily driven by a special cash dividend and the involvement of investor David Lazar, known for revitalizing distressed companies. The community is sharply divided, actively debating whether it signals a massive short squeeze fueled by low float and high short interest, or an impending pump-and-dump given dilution concerns and prior history. Many are closely analyzing the unique "due bills" dividend procedures and speculating on a potential pivot towards blockchain technology.

Polygon

Polygon is experiencing a surge in bullish sentiment driven by its increasing on-chain revenue and soaring network usage. The community is actively discussing its perceived undervaluation relative to competitors, especially given growing institutional adoption and the impact of token burning on scarcity. Major players leveraging its robust DeFi and payment infrastructure further fuel optimistic expectations.

Grayscale Investments LLC - Grayscale Bitcoin Trust

Grayscale Bitcoin Trust

Grayscale Bitcoin Trust (GBTC) is trending amid sharply divided community sentiment on Bitcoin's immediate future, with some anticipating a rapid parabolic ascent fueled by institutional interest and comparisons to gold, while others foresee a prolonged "crypto winter" and significant price corrections. The discussion heavily features debates on historical market cycles, recent ETF inflows and outflows, and concerns about potential market manipulation impacting Bitcoin's valuation.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

ProShares Ultra Bloomberg Natural Gas (BOIL) is trending due to extended forecasts for unseasonably warm weather, significantly suppressing heating demand and leading to continuous declines in natural gas prices. The community is sharply divided, with some hoping for a polar vortex to spark a reversal, while others caution against the leveraged ETF's historical decay and aggressive downside volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Best Value Stocks to Buy for May 28th

New Strong Buy Stocks for May 28th

Shares of Phio Pharmaceuticals Corp. (PHIO) traded 63% higher on Wednesday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://phiopharma.com/phio-pharmaceuticals-announces-positive-safety-monitoring-committee-recommendation-to-advance-intasyl-ph-762-skin-cancer-study-to-fourth-dose-escalation-cohort/">announced</a> that a Safety Monitoring Committee (SMC) recommended escalating the dose in the clinical trial for its lead product candidate, PH-762.The dose-escalating clinical trial aims to evaluate the safety and tolerability of neoadjuvant use of intratumoral PH-762 in certain skin cancers. The trial assesses tumor response and determines the recommended dose for further study of the product candidate.PH-762 is an Intasyl compound that silences the PD-1 gene implicated in various forms of skin cancer.CEO Robert Bitterman said the company is optimistic the clinical trial will continue to demonstrate that PH-762 may present a viable non-surgical alternative to existing modes of therapy for skin cancer.The company said that two of four patients diagnosed with cutaneous squamous cell carcinoma and enrolled in the second cohort of the trial had 100% tumor clearance upon excision.While one had a 90% tumor clearance, the fourth patient maintained stable disease, the company said.Three patients were enrolled in the third cohort of the trials. The injections were well tolerated with no serious adverse events, the company said.On Stocktwits, retail sentiment around Phio Pharmaceuticals rose from ‘bearish’ to ‘extremely bullish’ while message volume jumped from ‘high’ to ‘extremely high’ over the past 24 hours.<figure class="image"><img style="aspect-ratio:1298/298;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_09_at_1_47_54_PM_png_f2666fba4f.webp" alt="PHIO's Sentiment Meter and Message Volume as of 2:00 p.m. ET on April 9, 2025 | Source: Stocktwits" width="1298" height="298"><figcaption>PHIO's Sentiment Meter and Message Volume as of 2:00 p.m. ET on April 9, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/PHIO">PHIO shares</a> rose as high as $2.73 on Wednesday before paring gains to around $1.50.The stock fell by over 13% this year and by over 73% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/pacbio-plans-to-reduce-spending-over-nih-funding-uncertainty-tariffs/chfnXrfRbBd">PacBio Stock Soars On Plans To Reduce Spending Over NIH Funding Uncertainty, Tariffs: Retail Is Overjoyed</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Phio Pharmaceuticals Stock Soars On Clearance To Escalate Dose In Skin Cancer Treatment Trial: Retail’s Thrilled

CEO Robert Bitterman said the company is optimistic that the clinical trial will continue to demonstrate that PH-762 may present a viable non-surgical alternative to existing modes of therapy for skin cancer. 

Equity

CEO Robert Bitterman said the company is optimistic that the clinical trial will continue to demonstrate that PH-762 may present a viable non-surgical alternative to existing modes of therapy for skin cancer.

Shares of Phio Pharmaceuticals Corp. (PHIO) nearly&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/phio-stock-rockets-on-cancer-trial-data/chGNgCORNj">quadrupled</a> on Monday after the biotech firm announced promising results from its Phase 1b trial for the cancer immunotherapy PH-762, designed to enhance the immune system's ability to target tumors.However, the nanocap stock reversed course on Tuesday, plunging over 50% following news of a registered direct offering.Phio revealed agreements to sell 1.1 million common shares at $3 each, with a concurrent private placement issuing short-term warrants to purchase 2.1 million shares at the same price.&nbsp;The combined transactions are expected to generate approximately $3.2 million in gross proceeds, earmarked for working capital and other corporate purposes.Despite the sharp decline, retail investors remain optimistic, as evidenced by a Stocktwits poll where nearly 50% of over 900 participants believe the stock has "more room to run."&nbsp;Around 34% foresee a pullback, while 13% are uncertain due to the stock's volatility.Retail sentiment on Stocktwits turned 'extremely bullish' on Tuesday, with many users predicting a post-offering rally fueled by Phio's low float and the potential of its drug pipeline.&nbsp;Some highlighted the company's ongoing trial progress, while others saw the price drop as a buying opportunity.<stembedurl>https://stocktwits.com/pragash2094/message/599992949</stembedurl><stembedurl>https://stocktwits.com/HUBC1/message/599986181</stembedurl><stembedurl>https://stocktwits.com/TrendIsMyFriend/message/599998502</stembedurl>Like many early-stage biotech firms, Phio has yet to generate revenue. However, its latest financial report showed narrowed losses of $1.5 million for the quarter ended Sept. 30, compared to $2.8 million a year earlier.&nbsp;The company reported $5.4 million in cash, down from $8.4 million a year earlier but more than $4.7 million at the end of the previous quarter.The stock has lost nearly 50% of its value over the past year but has seen retail interest soar. The number of new followers on Stocktwits jumped by over 9%, while message volume increased more than 1,600-fold.With a short interest of 3.8% and ongoing developments in its PH-762 trial, retail investors remain laser-focused on updates about higher-dose concentrations and further enrollment milestones.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Phio’s stock has lost nearly 50% of its value over the past year but has seen retail interest soar. | Image source: Maria Korneeva on Getty Images

We Asked Retail What's Next For Phio Pharma After Monday's Blistering Rally: Most See More Room To Run

Around 34% foresee a pullback, while 13% are uncertain due to the stock's volatility.

Shares of Phio Pharmaceuticals Corp. surged 330% Monday afternoon, reaching their highest levels in nearly eight months, to become the top gainer across U.S. bourses.&nbsp;This explosive move followed the announcement of positive results from a Phase 1b trial of its cancer treatment, PH-762, which is designed to enhance the immune system’s ability to target tumors.&nbsp;Trading volume soared to over 220 times the daily average, drawing significant attention from retail investors.Phio revealed that patients in the second cohort of its ongoing trial exhibited these pathologic responses: Two patients with cutaneous squamous cell carcinoma experienced a complete response (100% tumor clearance); one patient had a partial response (90% tumor clearance); one patient maintained stable disease, with no progression.The trial focuses on evaluating PH-762 for neoadjuvant use in Stages 1, 2, and 4 cutaneous squamous cell carcinoma, Stage 4 melanoma, and Stage 4 Merkel cell carcinoma.&nbsp;Importantly, no dose-limiting toxicities or clinically relevant adverse events have been reported, and the intratumoral injections have been well tolerated, the company said.Mary Spellman, Acting chief medical officer of Phio, expressed optimism about the tumor responses, saying, “We look forward to continued enrollment which will permit assessment of higher dose concentrations of PH-762.”&nbsp;"These positive results in the early stages of dose escalation offer promise for our vision, 'striving for a cancer free future' using INTASYL technology" said CEO Robert Bitterman.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/PHIO_sentiment_meter_and_message_volume_Jan_13_38cb5ff222.png" alt="PHIO sentiment meter and message volume Jan 13.png" width="1318" height="324"><figcaption>PHIO sentiment meter and message volume Jan 13 as of 12:15 pm ET | source: Stocktwits</figcaption></figure>On Stocktwits, sentiment for Phio spiked to 'extremely bullish' levels, with users sharing optimistic price targets and success stories.<stembedurl>https://stocktwits.com/M105/message/599814732</stembedurl><stembedurl>https://stocktwits.com/Ian980/message/599806765</stembedurl><a href="https://stocktwits.com/symbol/PHIO">Phio’s stock</a> has gained nearly 15% over the past 12 months, with Monday’s rally marking a sharp shift in momentum.&nbsp;Investors are closely watching for further enrollment updates and results from higher dose concentrations in the ongoing trial.For updates and corrections, email newsroom[at]stocktwits[dot]com.

The trial focuses on evaluating PH-762 for neoadjuvant use in Stages 1, 2, and 4 cutaneous squamous cell carcinoma, Stage 4 melanoma, and Stage 4 Merkel cell carcinoma. | Image source: Getty Images

Phio Pharma Stock Quadruples On Positive Data From Cancer Treatment Trial: Retail’s Elated

CEO Robert Bitterman highlighted the potential of Phio’s proprietary INTASYL RNAi technology, which targets proteins that hinder the body’s immune response to cancer.

Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.

Phio Pharmaceuticals Corp

Yes — Rates Move Meaningfully Lower

Short-Term Dip, No Lasting Impact

No — Mostly Political Noise

Other – Comment Below

President Trump says he’s directing $200 billion into mortgage bond purchases to bring down rates and improve housing affordability. With questions around execution, authority, and real market impact, do you think this move will actually lower mortgage rates in 2026?

Will Trump’s Mortgage Bond Plan Actually Lower Rates in 2026?

PHIO
Phio Pharmaceuticals Corp

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest PHIO News

PHIOPhio Pharmaceuticals Corp